KRAS and pancreatic neoplasm: Direct targeting of KRAS has not been successful in patients with pancreatic cancer [6], so current research efforts have refocused on two downstream pathways, the phosphatidylinositol 3-kinase (PI3K)/AKT pathway [7] and the RAF/MEK pathway [8,9].